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Introduction: The recent findings of the National Lung Screening 
Trial showed 24.2% of individuals at high risk for lung cancer having 
one or more indeterminate nodules detected by low-dose computed 
tomography–based screening, 96.4% of which were eventually con-
firmed as false positives. These positive scans necessitate additional 
diagnostic procedures to establish a definitive diagnosis that adds 
cost and risk to the paradigm. A plasma test able to assign benign ver-
sus malignant pathology in high-risk patients would be an invaluable 
tool to complement low-dose computed tomography–based screen-
ing and promote its rapid implementation.
Methods: We evaluated 17 biomarkers, previously shown to have 
value in detecting lung cancer, against a discovery cohort, compris-
ing benign (n = 67) cases and lung cancer (n = 69) cases. A Random 
Forest method based analysis was used to identify the optimal bio-
marker panel for assigning disease status, which was then validated 
against a cohort from the Mayo Clinic, comprising patients with 
benign (n = 61) or malignant (n = 20) indeterminate lung nodules.
Results: Our discovery efforts produced a seven-analyte plasma 
biomarker panel consisting of interleukin 6 (IL-6), IL-10, IL-1ra, 
sIL-2Rα, stromal cell-derived factor-1α+β, tumor necrosis factor 
α, and macrophage inflammatory protein 1 α. The sensitivity and 
specificity of our panel in our validation cohort is 95.0% and 23.3%, 
respectively. The validated negative predictive value of our panel was 
93.8%.
Conclusion: We developed a seven-analyte plasma biomarker panel 
able to identify benign nodules, otherwise deemed indeterminate, 
with a high degree of accuracy. This panel may have clinical utility 
in risk-stratifying screen-detected lung nodules, decrease unneces-
sary follow-up imaging or invasive procedures, and potentially avoid 
unnecessary morbidity, mortality, and health care costs.
Key Words: Lung cancer, Nodules, Low-dose computed  tomography 
screening, Plasma biomarkers, Validation.
(J Thorac Oncol. 2013;8: 31–36)
The American Cancer Society estimates more than 226,160 new cases of lung cancer and approximately 160,340 lung 
cancer deaths in 2012, making it the most common cause 
of malignancy-related mortality in the United States.1 Non–
small-cell lung cancer (NSCLC) carries a dismal prognosis 
with a 5-year survival rate estimated to be less than 16%. 
Poor survival is partly because of the fact that 85% of lung 
cancer cases are diagnosed after metastatic disease progres-
sion, when curative treatment options are no longer available. 
Diagnosis of NSCLC before the development of extensive 
locoregional or distant metastases promises to improve 5-year 
survival rates by 60% to 80%.2 Efforts have been made since 
the early 1970s to identify screening methods for early detec-
tion of NSCLC. Unfortunately, neither chest radiography nor 
sputum cytology proved to be effective.3–6 Single-arm pro-
spective uncontrolled studies on low-dose computed tomog-
raphy (LDCT) of the chest screening yielded conflicting 
results.1,7 Recently, the National Lung Screening Trial (NLST) 
demonstrated a 20% relative reduction in lung cancer mor-
tality with LDCT screening of high-risk patients compared 
with annual chest radiograph with a median follow-up of 6.5 
years.8 High risk in patients was defined by this study to be 
individuals aged 55 to 74 years, having a smoking history of 
more than 30 pack-years, and having quit less than 15 years 
before randomization.
The approach to indeterminate screen-detected lung 
nodules in high-risk populations can represent significant 
challenges for the clinician. Data from the NLST showed that 
24.2% of screening LDCT scans were positive, with 96.4% 
of these nodules determined as false positives.8 An individual 
has an incidence of 33% of a false positive LDCT scan after 
two rounds of annual screening, and 7% of these individuals 
go through unnecessary invasive procedures to prove 
benign disease.9 Avoidance of these unnecessary invasive 
procedures would benefit patient safety. The analysis for the 
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cost-effectiveness of LDCT screening has not been reported by 
the NLST at this time. However, estimates from other groups 
have concluded the added cost of LDCT screening for lung 
cancer to approximate $1.3 billion to $2.0 billion, annually.9 
In addition, it is estimated to cost $240,000 per one life saved 
by LDCT screening.9 Decreasing the cost of LDCT screening 
by decreasing the need for subsequent invasive thoracic 
procedures or continued radiographic follow-up is paramount.
The potential of individual serum biomarkers to predict 
malignancy in indeterminate lung nodules has been researched 
and met with limited success. Published data on individual 
serum biomarkers, most notably cytokeratin 19 fragment 21.1, 
carcinoembryonic antigen, and tissue plasminogen activator in 
NSCLC show limited sensitivity and specificity, particularly in 
early-stage disease.10,11 The objective of our study is to develop 
and validate a plasma biomarker panel with test characteristics 
compatible with its use as a companion test in high-risk patients 
with screening LDCT-detected indeterminate lung nodules.
PATIENTS AND METHODS
Patient Cohorts
Between 2004 and 2010, we enrolled 136 patients at 
Rush University Medical Center (RUMC) and divided them 
into the following cohorts: (a) pathologically diagnosed 
lymph-node negative lung cancer (n = 69) and (b) benign 
disease (n = 67). All stage classifications were according to 
the 7th edition criteria12,13 and were pathologically confirmed. 
Patients with benign resected disease (n = 35) were diag-
nosed with granulomatous inflammation (n = 21), nonspecific 
inflammatory changes (n = 9), and lung infections (n = 5). 
The remaining patients in our benign cohort were part of an 
internal screening program with LDCT-determined benign 
disease (n = 32). Inclusion criteria for individuals enrolled 
in our screening program were ages of 50 years or more, or 
smoking history of more than 20 pack-years. All participants 
were followed with annual LDCT and remained cancer-free 
for a minimum 2-year follow-up. Demographic information 
for these patient groups are contained in Table 1. Our valida-
tion population (n = 81) consisted of the following cohorts 
received from our collaboration with the Mayo Clinic: (a) 
pathologically diagnosed lymph-node negative lung cancer 
(n = 20) and (b) benign disease (n = 61). Demographic infor-
mation is contained in Table 2. All patient data was acquired 
with written informed consent and in absolute compliance 
with the Institutional Review Board at either Rush University 
Medical Center or the Mayo Clinic.
Measurement of Plasma 
Biomarker Concentrations
Plasma was prepared using standard phlebotomy proto-
cols from peripheral blood collected in yellow-top tubes either 
immediately before an anatomical resection, or in conjunction 
with a lung cancer screening trial. No specimen was subjected 
to more than two freeze and thaw cycles.14–17 Seventeen can-
didate biomarkers were used for discovery based on previ-
ously shown success in differentiating NSCLC from benign 
disease.15 Assays for CA-125, cytokeratin 19 fragment 21-1, 
osteopontin, stromal cell-derived factor -1(α+β) (Millipore, 
Billerica, MA) were measured as a four-plex assay kit; inter-
leukin-1 receptor antagonist (IL-1ra), sIL-2Rα, IL-6, IL-10, 
Eotaxin, monocyte chemotactic protein 1, macrophage 
inflammatory protein-1α, tumor necrosis factor alpha (TNF-
α) (Millipore) as an eight-plex assay kit; and sE-Selectin, 
sICAM-1 (Millipore) as a two-plex assay kit. The remaining 
plasma biomarkers (Millipore) were run individually and con-
sisted of soluble epidermal growth factor receptor (sEGFR) 
matrix metalloproteinase 2, and C-reactive protein. All bio-
marker concentrations were calculated with a five-parametric 
curve fit, using xPONENT v4.0.3 (Luminex Corp., Austin, 
TX) in a blinded fashion, using data collected on a Luminex 
FlexMAP 3D system. Table 3 lists the 17 biomarkers evalu-
ated in this study.
Statistical Methods
Methods for candidate biomarker testing were consistent 
with those previously reported by our group.14–17 Descriptive 
statistics were obtained along with receiver operator charac-
teristics parameters (including area under the curve [AUC]) 
to assess the performance of the 17 individual candidate bio-
markers, using SPSS 18.0 for Windows (SPSS Inc., Chicago, 
IL). The Mann–Whitney rank sum test was used to evalu-
ate differences in biomarker concentrations. A threshold for 
TABLE 1.  Demographics for the Discovery Population from 
Rush University Medical Center
Benign 
Screening
Benign 
Resected
Lung Cancer
Sex
Male 14 (44) 19 (54) 29 (42)
Female 18 (56) 16 (46) 40 (58)
Age, yr
Median 61 65 67
Range 51–82 20–80 48–83
Smoking history, pack-years
Median 36 1 35
Nonsmoker 06–26 0–60 0–120
Nodule size, mm
Median 4 14 18
Range 2–17 4–75 7–175
TNM
T
1
N
0
M
0
51
T
2
N
0
M
0
13
T
3
N
0
M
0
02
T
4
N
0
M
0
00
Histologic diagnosis
Adenocarcinoma 49 (72)
Squamous cell 10 (14)
Neuroendocrine 0 10 (14)
Benign diagnosis
Granuloma 21 (60)
Inflammation 09 (26)
Infection 05 (14)
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significance as a biomarker was set to an AUC of greater than 
0.60 or a Mann–Whitney rank sum (2-sided) p value less than 
0.05. The optimal multivariate panel was selected using vari-
able selection based on importance scores from the Random 
Forests method as we previously described.14 Sensitivity, 
specificity, and negative predictive value were used to evalu-
ate performance of our biomarker panel. The biomarker panel 
selected, based on data from the discovery cohort, was then 
used to make predictions of disease in our validation cohort 
(Mayo Clinic, Rochester, MN) in a blinded fashion (where the 
statistician is kept completely blinded of the true disease sta-
tus data in the validation cohort).
RESULTS
The median age of the patients with benign disease 
in our screening cohort was 61 years whereas our benign 
resected cohort’s median age was 65 years (range, 20–82). 
In comparison, the median age of patients in our lung cancer 
cohort was 67 years (range, 48–83). The median pack-year 
smoking history of patients with benign disease in our 
screening cohort was 36 pack-years (range, 6–126) whereas 
our benign resected cohort’s median smoking history was 
1 pack-year (range, 0–60). The median pack-year smoking 
history of our lung cancer cohort was 35 pack-years (range, 
0–120). Univariate analysis of the RUMC discovery cohort 
data, using receiver operator characteristics curve parameters, 
revealed nine biomarkers of the 17 tested with an AUC more 
than 0.60, and eight biomarkers to be significantly different in 
indeterminate nodules between the lung cancer and the benign 
disease groups, as shown in Table 3. Four biomarkers showed 
strong significance (p < 0.01) for identifying lung cancer in 
indeterminate nodules and include IL-1ra, IL-10, CA-125 
and sE-Selectin. All four biomarkers were shown to have 
significantly elevated levels in patients with lung cancer.
Multivariate analysis of the data from only the RUMC 
discovery cohort patients, using variable selection based on 
Random Forests method, resulted in a seven-analyte panel 
consisting of IL-6, IL-10, IL-1ra, sIL-2Rα, SDF-1α+β, TNF-
α, and MIP-1α. This Random Forest–generated panel dif-
ferentiated patients with NSCLC from patients with benign 
disease with a crossvalidated accuracy of 76.5%. This panel 
provided 35 cases of true negatives, 69 cases of true positives, 
32 cases of false positives, and zero cases of false negatives 
for a calculated sensitivity of 100%, specificity of 52.2%, and 
a negative predictive value of 100%. The AUC was calculated 
to be 0.910 (Fig. 1).
The Random Forest–generated seven-analyte panel 
developed on the Rush Cohort was then used to predict the 
disease status in the validation cohort from the Mayo Clinic in 
a blinded fashion. The panel differentiated patients with lung 
cancer (n = 20) from patients with benign disease (n = 61) with 
an accuracy of 42.0%. This panel provided 15 cases of true 
negatives, 19 cases of true positives, 46 cases of false positives, 
and one case of false negative for a calculated sensitivity of 
95.0%, specificity of 24.6%, and a negative predictive value of 
93.8%. The AUC was calculated to be 0.676 (see Fig. 2).
DISCUSSION
The primary goal of LDCT screening programs is to 
detect asymptomatic disease in patients at high risk for lung 
TABLE 2.  Demographics for the Validation Population from 
the Mayo Clinic
Benign Resected Lung Cancer
Sex
 Male 30 (49) 12 (60)
 Female 31 (51) 08 (40)
Age, yr
 Median 63 64
 Range 30–83 49–82
Smoking history, pack-years
 Median 25 35
 Nonsmoker 0–100 0–100
Nodule size, mm
 Median 14 22
 Range 3–50 8–80
TNM
 T
1
N
0
M
0
14
 T
2
N
0
M
0
05
 T
3
N
0
M
0
01
 T
4
N
0
M
0
00
Histologic diagnosis
 Adenocarcinoma 10 (50)
 Squamous cell 05 (25)
 Neuroendocrine 05 (25)
TABLE 3.  All Biomarkers Analyzed for all Patients in the 
RUMC Discovery Population
Biomarker Abbreviation
Univariate  
Statistics
pa AUC
Interleukin 1 receptor antagonist IL-1ra < 0.001 0.909
Interleukin 10 IL-10 <0.001 0.742
Cancer antigen 125 CA-125 <0.001 0.728
Soluble endothelial selectin (CD62E) sE-Selectin <0.002 0.696
Tumor necrosis factor alpha TNF-α <0.011 0.673
Soluble epidermal growth factor receptor sEGFR <0.016 0.644
Macrophage inflammatory protein 1 alpha MIP-1α <0.018 0.640
Stromal cell-derived factor 1 a + b SDF-1α+β <0.029 0.658
Osteopontin OPN <0.074 0.647
C-reactive protein CRP <0.209 0.576
Matrix metalloproteinase 2 MMP-2 <0.324 0.548
Monocyte chemotactic protein 1 MCP-1 <0.378 0.539
Soluble intercellular adhesion molecule 1 sICAM-1 <0.690 0.546
Cytokeratin 19 fragment CYFRA 21.1 <0.783 0.520
Interleukin 6 IL-6 <0.868 0.538
Eotaxin Eotaxin <0.972 0.521
Soluble interleukin 2 receptor antagonist sIL-2Rα <1.000 0.508
aMann–Whitney rank sum test (2-sided).
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cancer, therefore, increasing eligibility for surgical interven-
tion with curative intent and greatly improving prognosis. 
Currently, an estimated 7 million individuals in the United 
States qualify for lung cancer screening, based on the NLST 
inclusion criteria.8 If CT-based screening protocols were 
implemented today, the health care system would be burdened 
by the 1.6 to 3.5 million indeterminate nodules identified 
by LDCT screening.18,19 Under current guidelines, positive 
screening LDCT scans are stratified by nodule size to deter-
mine lung cancer risk and diagnostic recommendations. It is 
recommended that nodules less than 4 mm, 4 to 6 mm, and 6 
to 8 mm are followed by LDCT screening at annual, 6-month, 
and 3-month intervals, respectively.20 Nodules greater than 
8 mm should be investigated further with positron emission 
tomography scan and/or biopsy. A significant number of 
patients will undergo invasive procedures to further character-
ize these indeterminate nodules, and according to the NLST 
data, 96% of those nodules will prove to be benign.
As a result of the NLST trial, the International 
Association for the Study of Lung Cancer (IASLC) recently 
published a position statement with regard to LDCT screen-
ing.21 The IASLC appointed a Strategic CT Screening 
Advisory Committee (SSAC) to deliver guidelines and rec-
ommendations in six key areas of LDCT screening. One 
specific focus of the SSAC was to develop guidelines for 
the clinical workup of indeterminate nodules resulting from 
LDCT screening. Within these guidelines, the IASLC–SSAC 
recognized the need for further investigation of biomarkers 
as a complement to address the high number of false-positive 
cases with LDCT screening.21 LDCT screening, with success-
ful discovery of biomarkers capable of increasing its efficacy, 
can evolve into a universally available tool for clinicians.
Our discovery effort for the development of our plasma 
biomarker panel refined previous efforts made by our group 
to develop a serum biomarker panel capable of predicting 
NSCLC versus benign disease.14–17 We reevaluated significant 
biomarkers, which previously showed value in serum for 
predicting NSCLC versus benign disease, and used them to 
determine value in plasma for predicting NSCLC versus benign 
disease in patients with indeterminate nodules. Large national 
cancer repositories have focused efforts to store plasma for the 
development and validation of biomarker panels.22 As a result, 
the use of plasma as the matrix for discovery and validation 
is crucial for future validations. Our plasma biomarker panel 
consisted of IL-6, IL-10, IL-1ra, sIL-2Rα, SDF-1α+β, TNF-
α and MIP-1α. Our plasma panel biomarker shares three 
analytes (IL-1Rα, TNF-α, MIP-1α) with our previous serum 
biomarker panel, which was successful for predicting NSCLC 
versus benign disease.15 Our plasma biomarker panel was able 
to predict lung cancer versus benign disease in our discovery 
cohort with an accuracy of 76.5%. Our panel accuracy was 
affected by a larger than expected number of false-positive 
cases (n = 32). The clinical value of our plasma biomarker 
panel is its ability to effectively rule out lung cancer in 
patients with indeterminate nodules when the panel predicts 
benign disease (negative predictive value). The negative 
predictive value of our plasma biomarker test was 100% in our 
discovery cohort, with no false-negative cases observed. The 
observed high sensitivity (100%) and high negative predictive 
value (100%) of our plasma biomarker panel in our discovery 
cohort was suspect for apparent overfitting of the data, despite 
attempts to avoid this bias with Random Forest multivariate 
analysis. Validation studies, however, demonstrated that this 
was not the case.
Blinded validation of our plasma biomarker panel 
was performed against an external cohort of patients in 
collaboration with investigators from the Mayo Clinic. The 
difficulty in our ability to accurately predict lung cancer 
versus benign disease (41.3%) in our validation cohort was 
again the result of an increased number of false-positive 
cases (n = 46) and not as a result of false-negative cases. The 
negative predictive value of our test in our validation cohort 
remained high at 93.8%, with only one false-negative case. 
FIGURE 1.  Receiver operator characteristics curves for 
optimal panel in our RUMC discovery cohort. Area under the 
curve = 0.910 with a sensitivity of 100% and specificity of 
52.2%. RUMC, Rush University Medical Center.
FIGURE 2.  Receiver operator characteristics curves for opti-
mal panel in the Mayo Clinic validation cohort. Area under 
the curve = 0.676 with a sensitivity of 95.0% and specificity 
of 24.6%.
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Despite an increased number of false-positive cases in our 
validation cohort, the clinical value of our plasma biomarker 
panel is unaffected. The panel’s ability to effectively rule out 
lung cancer in patients with indeterminate nodules, when the 
panel predicts benign disease, remains unchanged by false 
positives. Our plasma biomarker panel would have accurately 
captured 15.4% of patients, who would otherwise have 
undergone unnecessary surgical biopsy, and moved them to 
a more conservative treatment arm of serial LDCT screening.
Despite a sensitivity of 100% and 95% in our discovery 
and validation cohort, respectively, the specificity remained low 
(52.2% and 23.3%, respectively) in the two cohorts. Although 
our biomarker panel is efficient at finding disease in a patient 
with lung cancer, our panel is poor at singling out patients with 
benign disease. This is a result of 32 and 46 false-positive cases 
in our discovery and validation cohort, respectively. Despite 
the low specificity of our biomarker panel, our panel could lead 
to significant reduction in morbidity, mortality, and health care 
costs. In fact, the current cost of materials and labor per patient 
for the Luminex-based plasma test presented in this study is 
$48, making this cost-effective and capable of being performed 
at most hospitals and medical centers across the United States. 
Efforts are currently ongoing in our laboratory to identify new 
biomarkers, using proteomic and immunoproteomic methods 
to improve the overall accuracy of our plasma test. In addi-
tion, efforts will be made to expand our cohorts to include a 
larger percentage of patients with squamous cell carcinoma, as 
this subgroup provides unique tumor antigens that enhance the 
overall value to our plasma biomarker panel.
Few other blood tests seem ready for clinical use for 
assigning clinical significance to indeterminate nodules. Two 
such panels include the EarlyCDT-Lung test manufactured 
by Oncimmune, Limited (Nottingham, Great Britain)23,24 and 
a multianalyte serum biomarker panel by Bigbee et al.25 The 
EarlyCDT-Lung test consists of autoantibodies against p53, 
NY-ESO-1 (cancer-testis antigen), cancer-associated antigen, 
GBU4-5, annexin I, and SRY
(sex determining region Y)
-box 2 (SOX2), 
and has been extensively tested and validated against early-
stage lung cancer patients and control patients.23,24 However, 
clinical validation of this test provides an average sensitivity 
of 39% and specificity of approximately 90%. More recently, 
Bigbee et al.25 reported the validation of an eleven-analyte 
serum biomarker panel for predicting the level of cancer risk 
in high-risk individuals with indeterminate lung nodules.25 
This serum biomarker panel consisted of prolactin, transthyre-
tin, thrombospondin-1, sE-selectin, C-C motif chemokine 5 
(CCL5; RANTES), macrophage migration inhibitory fac-
tor (MIF), plasminogen activator inhibitor, tyrosine-protein 
kinase, erbb-2, cytokeratin fragment 19 (CYFRA 21-1), and 
serum amyloid A (SAA). The serum biomarker panel achieved 
a sensitivity and specificity of 73.3% and 93.3%, respectively 
in their validation cohort.25 The positive predictive value of the 
published serum panel was an impressive 92.3%, however, this 
feature will have a modest clinical impact because of the fact 
that confirming cancer in these patients does not change the 
treatment plan as all, regardless, will receive subsequent inva-
sive procedures. Alternatively, the negative predictive value of 
the Bigbee et al.25 serum biomarker panel in validation studies 
was very good at 77.8% and will help clinical management of 
a screening population. We intend to explore some of the bio-
marker targets identified by this study as a means to improve 
the positive predictive value of our panel.
In conclusion, we have developed a test with a negative 
predictive value, which will allow clinicians to confidently 
rule out malignancy in indeterminate pulmonary nodules 
found during LDCT screening. In addition to the cost advan-
tage to the health care system, this assay may offer rapid 
result capability (< 24 hours) and will reduce patient anxi-
ety inherent in current diagnostic methods, which may take 
as long as 6 months to complete. To continue in our objective 
to bring a highly functioning plasma biomarker panel to clini-
cal use, our next step includes a large-scale validation with 
cooperation of the Early Detection Research Network and the 
American College of Radiology Imaging Network-National 
Lung Screening Trial. Furthermore, a large-scale proteomic 
discovery approach will soon be initiated, which will allow 
us to improve our positive predictive value and generate 
a more optimal version of our test for clinical implementa-
tion. Successful large-scale validation will allow our group to 
employ our plasma biomarker panel in large prospective clini-
cal trials with the ultimate goal of producing a highly efficient 
tool for clinicians to use in their practice.
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